Transaction · 0001950232-26-000003

Reardon Andrew

Reardon Andrew, CLO, SECY, reported an open-market or private sale at LIGAND PHARMACEUTICALS INC involving 404.000000 shares for an estimated $123698.09. Reported holdings after the transaction were 32106.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCLO, SECY
LGNDLIGAND PHARMACEUTICALS INC
Filing timeOct 06
Trade dateOct 02, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded1.24%Shares sold ÷ (holdings after + shares sold). Estimated position before: 32,510 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$296.94
Pre-filing
1mo ago -4.5%1w ago +1.5%1d ago +2.0%
Returns since
7d30d90d180d1y

LGND price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
LGND since 2026-10-06Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001950232-26-000003
Common Stock
Transaction date
Oct 02, 2026
Filed Oct 06, 2026, 08:35 PM · 4d delay
Shares
404 sh
$306.18 per share
Estimated value
-$123k
Computed from shares × price
Holdings after
32.1k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CLO & Secretary

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.

  2. F2

    The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Re…

  3. F3

    The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Re…

  4. F4

    The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Re…

  5. F5

    The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Re…

  6. F6

    The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Re…

  7. F7

    The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Original filing · 0001950232-26-000003
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

LGND